Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
News|Videos|January 25, 2019
Immunotherapy Pair Good for Some, Not All, With Kidney Cancer
Author(s)Sumanta K. Pal, M.D.
Yervoy plus Opdivo is a good combination for many patients with kidney cancer, though some individuals should steer clear of the regimen.
Advertisement
While the immunotherapy duo Yervoy (ipilimumab) and Opdivo (nivolumab) works well for many patients with kidney cancer, the regimen is not for everyone, explained Sumanta K. Pal, M.D., associate clinical professor in the Department of Medical Oncology and Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope.
This therapy may not be best for patients with good-risk disease or who have autoimmune conditions or concerns. Instead, these patients will often do better on tyrosine kinase inhibitor (TKI) drugs, such as Cabometyx (cabozantinib), according to Pal.
Advertisement
Related to this article
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
3
Life After a Prostate Cancer Diagnosis: Why It’s a Pivot, Not an Ending
4
3 Quality-of-Life Results From ESMO 2026 Patients Should Know
5